The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2026 | Multimodal treatment approaches for resectable NSCLC
Rene Petersen, MD, PhD, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, explores the current landscape of multimodal treatment approaches for resectable non-small cell lung cancer (NSCLC), highlighting that 5 trials have shown that neoadjuvant or perioperative chemoimmunotherapy increases survival. The complexity of surgery following chemoimmunotherapy is increasing, requiring more advanced surgical tools including the use of robotic surgery. This interview took place at the 2026 European Lung Cancer Congress in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
